Skip to content

Individualized Lifestyle Intervention for Obesity Management Based on Obesity Phenotypes

Mayo Clinic Diet Individualized Lifestyle Intervention for Obesity Management Based on Obesity Phenotypes (PHENO-Diet Trial)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04073394
Enrollment
215
Registered
2019-08-29
Start date
2020-07-06
Completion date
2022-01-31
Last updated
2023-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

The purpose of this protocol is to define an individualized diet approach based on obesity related phenotypes (pathophysiology obesity classification), which would increase weight loss, adherence, and weight loss maintenance.

Interventions

Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the Mayo Clinic Diet program.

BEHAVIORALModified Lifestyle Intervention

Research team will prescribe diet, exercise, behavioral plan for the participant to follow for the 12 week study. The lifestyle plan will be based on the participants obesity phenotype.

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Adults with obesity (BMI \>30Kg/m2); these will be otherwise healthy individuals with no unstable psychiatric disease and uncontrolled life-threatening comorbidities (i.e. unstable angina). * Age: 18-65 years. * Gender: Men or women.

Exclusion criteria

* Weight change greater than 3% in the previous 3 months (weight stable). * History of bariatric surgery including lap band and bariatric endoscopy. * Significant untreated psychiatric dysfunction including binge eating disorders and bulimia. * Current use of anti-obesity pharmacotherapy, medications known to affect weight (e.g., corticosteroids) or GLP-1 agonist/analog for T2DM * A positive score on the AUDIT-C questionnaire as judged by an investigator. * Patient has a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder study adherence

Design outcomes

Primary

MeasureTime frameDescription
12-week total body weight loss12 weeksChange in body weight during the 12 week study

Secondary

MeasureTime frameDescription
Waist Circumference12 weeksChange in waist circumference (cm)
Fat Loss12 weeksChange in fat mass during the 12 week study using DEXA
Calorie Intake12 weeksChange in daily calorie intake
Calories to Fullness12 weeksChange in calories consumed to fullness during the 12 week study using satiation test
Gastric Emptying12 weeksChange in half gastric emptying time during the 12 week study using scintigraphy
Responder Rate12 weeksProportion of patients losing \> 3% of total body weight
Anxiety Level12 weeksChange is anxiety level during the 12 week study using the HADS-A scale
Emotional Eating12 weeksChange is emotional eating level during the 12 week study using the TFEQ score
Resting Metabolic Rate12 weeksChange in resting energy expenditure during the 12 week study using an indirect calorimetry
Adherence12 weeksAdherence and compliance with program defined by the number of contacts with the team
Gastric Emptying 2 Hours12 weeksChange in gastric emptying percentage at 2 hours during the 12 week study using scintigraphy

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026